Intra-Cellular Therapies v. Aurobindo: ANDA Patent Battle Over CAPLYTA® Consolidated in New Jersey

Case Overview

In a significant pharmaceutical patent enforcement action, Intra-Cellular Therapies, Inc. (ITCI) secured procedural consolidation of its sprawling ANDA-related patent infringement litigation against multiple generic drug manufacturers — including Aurobindo Pharma Ltd. and Aurobindo Pharma USA, Inc. — before the U.S. District Court for the District of New Jersey. Case No. 3:24-cv-10235, filed November 1, 2024, and closed just 70 days later on January 10, 2025, represents one piece of a broader litigation campaign by ITCI to protect its branded psychiatric medication CAPLYTA® (lumateperone) capsules, 42 mg, from generic competition.

This case matters beyond its procedural resolution. It illustrates how branded pharmaceutical companies deploy multi-defendant, multi-wave ANDA litigation strategies to maximize 30-month stays under Hatch-Waxman, extend market exclusivity, and coordinate enforcement across a crowded field of generic challengers. For patent attorneys, IP professionals, and R&D teams operating in the CNS therapeutics space, this litigation offers critical strategic intelligence.

The Parties

The Patents at Issue

Three relatively recent patent grants form the core of this action, reflecting ITCI’s continued prosecution activity around lumateperone’s formulation, method of use, and compound claims:

• • U.S. Patent No. 12,128,043 B2
• • U.S. Patent No. 12,122,792 B2
• • U.S. Patent No. 12,090,155 B2

Their late application numbers suggest these are continuation or continuation-in-part filings, a common strategy to extend patent portfolio coverage and reset litigation timelines.

The Accused Product

The accused product is **lumateperone capsules, 42 mg** — the generic equivalent of CAPLYTA®, as described in Aurobindo’s ANDA submission. The commercial stakes are substantial given CAPLYTA®’s positioning in the competitive CNS therapeutics market.

Legal Representation

ITCI was represented by **Walsh Pizzi O’Reilly Falanga LLP**, with attorneys **Liza M. Walsh**, **Katelyn O’Reilly**, and **Lauren Ruth Malakoff** appearing on record. Defendant counsel information was not publicly disclosed in the available case record.

Litigation Timeline & Procedural History

ITCI’s enforcement campaign against generic lumateperone competitors launched in late March 2024 with the filing of Civil Action No. 3:24-cv-04264 against Aurobindo on **March 27, 2024**, followed immediately by six additional actions against Alkem Laboratories, Dr. Reddy’s Laboratories, Hetero, MSN Laboratories, Sandoz, and Zydus on **March 28, 2024**.

A second wave of related actions — Civil Action Nos. 3:24-cv-08845 through 3:24-cv-08856 — was filed on **August 29, 2024**, targeting the same seven defendants, likely reflecting subsequent ANDA submissions or additional patent listings in the FDA’s Orange Book.

Case No. 3:24-cv-10235 was filed **November 1, 2024**, and closed **January 10, 2025** — a compressed 70-day lifecycle consistent with a procedural resolution rather than merits adjudication. The basis of termination was **case consolidation**, folding this action into the broader coordinated litigation. New Jersey’s District Court is a preferred venue for Hatch-Waxman ANDA litigation given its judicial familiarity with pharmaceutical patent disputes and proximity to major industry participants.

The Verdict & Legal Analysis

Outcome

Case No. 3:24-cv-10235 was **closed via consolidation** on January 10, 2025. No merits determination — on infringement, validity, or damages — was reached in this specific action. The case was folded into the consolidated proceedings anchored by Civil Action No. 3:24-cv-04264, centralizing the multi-defendant ANDA litigation before a single docket for coordinated case management.

No damages were awarded, and no injunctive relief was issued in this specific action, as the resolution was purely procedural.

Verdict Cause Analysis

The infringement action arose under **35 U.S.C. § 271(e)(2)**, the Hatch-Waxman provision that treats an ANDA filing referencing a patented drug as an act of infringement sufficient to trigger litigation and the associated 30-month regulatory stay. ITCI’s strategy — filing successive waves of suits across seven defendants — reflects a sophisticated understanding of Hatch-Waxman mechanics.

By filing multiple actions and securing consolidation, ITCI accomplished several objectives simultaneously: coordinating discovery, managing litigation costs across a large defendant pool, preventing inconsistent rulings, and maintaining maximum pressure on generic entrants during the stay period. The rapid 70-day closure of Case No. 3:24-cv-10235 into consolidated proceedings is procedurally efficient and strategically sound.

The three patents at issue — US12128043B2, US12122792B2, and US12090155B2 — with their high application numbers suggest recent continuations, potentially covering formulation specifics, dosage regimens, or refined compound claims. Continuation strategies are particularly valuable in ANDA litigation because they allow branded companies to add newly issued patents to the Orange Book, triggering additional 30-month stays even after initial litigation has commenced.

Legal Significance

This case exemplifies the **multi-wave, multi-defendant ANDA enforcement model** increasingly favored by branded pharmaceutical companies with high-value CNS assets. The consolidation outcome itself — while not precedential on the merits — confirms that New Jersey courts are receptive to coordinating these complex, overlapping proceedings efficiently.

For practitioners, the filing pattern signals that ITCI’s Orange Book listings across these three patents may face paragraph IV certifications from multiple ANDA filers simultaneously or in sequence, creating layered litigation exposure for each generic challenger.

Strategic Takeaways

For Patent Holders: Continuation prosecution supporting new Orange Book listings can multiply Hatch-Waxman stay protections and sustain market exclusivity well beyond the original patent term. ITCI’s aggressive continuation strategy across three recently issued patents is a replicable model for CNS and specialty pharmaceutical IP portfolios.

For Accused Infringers: Generic manufacturers facing coordinated multi-defendant ANDA litigation should evaluate inter partes review (IPR) petitions at the USPTO as a parallel challenge to validity, potentially offsetting district court timelines. Coordination among co-defendants on claim construction positions and prior art can reduce litigation costs significantly.

For R&D Teams: Freedom-to-operate (FTO) analyses for CNS therapeutic formulations must account not only for base compound patents but for continuation families covering dosage forms, treatment regimens, and manufacturing processes. ITCI’s portfolio architecture illustrates how layered prosecution creates FTO complexity for generic developers years after initial compound protection.